Global Newsroom | CSL
WEBHead-to-head data, presented at OPTIONS XII for the Control of Influenza Conference, demonstrates advantage of sa-mRNA over conventional mRNA in duration of immune response; Results highlight CSL... Read more news from CSL
News Releases - CSL
WEBSep 30, 2024 — Recent News Releases. For investor-related news, see our ASX releases here. Basic Search. Head-to-head data, presented at OPTIONS XII for the Control of Influenza Conference, demonstrates advantage of sa-mRNA over conventional mRNA in duration of immune response; Results highlight CSL...
News Releases - CSL
WEBMay 20, 2024 — Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced top-line results from the Phase 3 AEGIS-II trial evaluating the efficacy and safety of CSL112 (apolipoprotein A-I [human])...
News Releases | CSL
WEBPart of a A$2 billion infrastructure investment program in Australia undertaken by CSL over the past four years, the facility will house more than 850 professionals dedicated to protecting public health and bringing life-saving innovative therapies to those in need.
Celebrating CSL's New Research and Development Center in …
WEBFor three years, anticipation has been building for the completion of CSL’s new R&D site in Marburg, Germany. On Tuesday, the doors opened for a launch event that showcased the state-of-the-art space, which will be powered by 500 R&D employees.
News Releases | CSL
WEBStudy results presented for first time at 2023 AAAAI Annual Meeting; global regulatory submissions anticipated later in the calendar year. Garadacimab underscores CSL's promise to develop innovative medicines for people living with rare diseases like HAE, a community CSL has been serving for 40 years.
Japan's Ministry of Health, Labor and Welfare Approves CSL and …
WEBSep 13, 2024 — Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma. Approval underscores CSL and Arcturus Therapeutics' commitment to delivering disruptive technologies to combat COVID-19 and ...
News Releases - CSL
WEBMay 30, 2024 — CSL Seqirus Begins Shipping Portfolio of Innovative Influenza Vaccines for the 2023/24 U.S. Season. CSL Seqirus is the only influenza vaccine manufacturer that offers differentiated vaccine options for individuals six months of age and older. Since the COVID-19 pandemic, there has been a... May 21, 2023.
News Releases | CSL
WEBDec 14, 2021 — Expands CSL’s leadership across an attractive portfolio focused on Renal Disease, and Iron Deficiency; Complements CSL’s existing therapeutic focus areas including Hematology and Thrombosis, Cardiovascular-Metabolic, and …
News Releases | CSL
WEBNov 2, 2022 — CSL revealed progress and plans in advancing assets that have the potential to disrupt current standards of care in its areas of focus (immunology, haematology, respiratory, cardiovascular and metabolic, transplant, nephrology, vaccines) using its strategic scientific platforms (plasma protein technology, …